

## **SUVEN Life Sciences**

#### Communication to investors Mar 2015

#### **Risk statement**



Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

#### FINANCIAL QUICK VIEW Quarter 4 – Mar 2015



- Growth in revenue
- Growth in PAT
- Growth in EBIDTA
- Growth in Pre-R&D EBIDTA
- Increase in R&D costs
- R&D cost on revenue

-13.28% -47.70% -45.46% -31.13% 25.18% 13.54%



#### FINANCIAL QUICK VIEW Year ending – Mar 2015

- Growth in revenue
- Growth in PAT
- Growth in EBIDTA
- Growth in Pre-R&D EBIDTA
- Increase in R&D costs
- R&D cost on revenue


3.14% -24.56% -24.34% -17.05% 16.72% 10.57%

# MAJOR PROFITABILITY RATIOS

	Q4 Mar 15	YE Mar 15
PAT to Income	14.81%	20.54%
EBIDTA to Income	23.17%	31.74%
Cash Flow to Income	17.14%	22.76%
Pre-R&D EBITDA to Income	36.71%	42.31%




#### **INCOME COMPARISON**






#### **PROFIT COMPARISON**






### EBIDTA COMPARISON






#### R & D – EXPENDITURE




#### PRE-R&D EBIDTA





#### PRE-R&D CASHFLOW





### Updates for the quarter

- Suven has 743 product patents for 26 inventions and 37 process patents for 7 inventions
- SUVN-502 completed phase 1b clinical trial in USA is in preparation for Phase 2a (POC) study on patients in USA
- SUVN G-3031 undergoing phase 1 clinical trial in USA
- SUVN D-4010 undergoing IND enabling toxicological studies in USA in preparation for Phase 1 clinical trial.
- Number of active CRAMS projects 110
- The Board has proposed a Dividend of Re.0.60 per share (60% of face value Rs. 1.00 each) for the financial year 2014-15, subject to approval of the shareholders in the ensuing Annual General Meeting.